A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (S�o Gon�alo do Amaranto, RN)

Silva, Valdemir Oliveira da; Borja-Cabrera, G.P.; Pontes, Nubia N.; Souza, Edilma Paraguai de; Luz, Kléber Giovanni; Palatnik, Marcos; Palatnik-de-Sousa, Clarisa B.

doi:10.1016/s0264-410x(00)00339-x

Cited by 113 publications

(134 citation statements)

References 26 publications

Supporting

Mentioning

121

Contrasting

Unclassified

Order By: Relevance

“…A multidisciplinary group of researchers have long been studying the FML-vaccine 7,46 . A field study in a LV-endemic area of Rio Grande do Norte State showed that this vaccine induced a significant long lasting and strong protective effect against canine visceral leishmaniasis 7 .…”

Section: Canine Vaccination: a Current Discussionmentioning

confidence: 99%

Visceral leishmaniasis in Brazil: revisiting paradigms of epidemiology and control

Dantas‐Torres

Brandão-Filho

2006

Rev. Inst. Med. trop. S. Paulo

165

View full text Add to dashboard Cite

SUMMARYIn the last 20 years, despite the known underestimation of cases, Brazil registered a marked increase in the incidence of visceral leishmaniasis. The main goal of this review is to reflect on some aspects of this zoonosis in Brazil and also to encourage the discussion in order to find more viable, effective and affordable strategies to be implemented by the Brazilian Leishmaniasis Control Program. The current situation of visceral leishmaniasis in Brazil might be seen as a paradox: the most important aspects of the disease are known, but so far the control of this disease has not yet been achieved. The current control strategies have not been able to prevent the geographical expansion, and even a rise in the incidence and lethality of visceral leishmaniasis. There is a need not only for a better definition of priority areas, but also for the implementation of a fieldwork monitoring system to the disease surveillance that could permit a further evaluation of the control program in areas where visceral leishmaniasis is endemic.

show abstract

Section: Canine Vaccination: a Current Discussionmentioning

confidence: 99%

Visceral leishmaniasis in Brazil: revisiting paradigms of epidemiology and control

Dantas‐Torres

Brandão-Filho

2006

Rev. Inst. Med. trop. S. Paulo

165

View full text Add to dashboard Cite

show abstract

“…Preliminary experiments with a vaccine prepared from L. (V.) braziliensis combined with BCG gave promise , but the Phase III trials led to the conclusion that the vaccine "did not appear to protect the dogs against visceral leishmaniasis" (Genaro et al 1996). The "Fucose-Mannose ligand" (FML), a complex glycoproteic fraction isolated from an aqueous extract of L. (L.) donovani, has been used in conjunction with a saponin adjuvant in attempts to vaccinate dogs against L. i. chagasi (Silva et al 2000). The authors regarded the vaccine as a promising tool in the control of canine visceral leishmaniasis in endemic areas of AVL.…”

Section: Controlmentioning

confidence: 99%

Lutzomyia longipalpis and the eco-epidemiology of American visceral leishmaniasis, with particular reference to Brazil: a review

Lainson

Rangel

2005

Mem. Inst. Oswaldo Cruz

391

238

View full text Add to dashboard Cite

show abstract

“…Domesticated and wild dogs are the main reservoir of the disease [16]. Because drug treatment of infected dogs is expensive and poorly effective and because there is no effective vaccine for yet ready use despite many trials [5,12,18], elimination of seropositive animals has been used in some countries [16] where visceral leishmaniasis is zoonotic as a means to control the human disease.…”

Section: Introductionmentioning

confidence: 99%

Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis

et al. 2005

View full text Add to dashboard Cite

-Control of canine visceral leishmaniasis (VL) remains a difficult and serious problem mostly because there is no reliable and effective vaccine available to prevent this disease. A mixture of three recombinant leishmanial antigens (TSA, LeIF and LmSTI1) encoded by three genes highly conserved in the Leishmania genus have been shown to induce excellent protection against infection in both murine and simian models of cutaneous leishmaniasis. A human clinical trial with these antigens is currently underway. Because of the high degree of conservation, these antigens might be useful vaccine candidates for VL as well. In the present study, using the dog model of the visceral disease, we evaluated the immunogenicity of these three antigens formulated with two different adjuvants, MPL-SE ® and AdjuPrime ® . The results were compared with a whole parasite vaccine formulated with BCG as the adjuvant. In order to investigate if sensitization with the recombinant antigens would result in recognition of the corresponding native parasite antigens upon infection, the animals were exposed for four weeks after the termination of the immunization protocol with the recombinant antigens to a low number of L. chagasi promastigotes, an etiological agent of VL. Immune response was evaluated by quantitative ELISA in the animal sera before and after exposure

show abstract

A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (S�o Gon�alo do Amaranto, RN)

Cited by 113 publications

References 26 publications

Visceral leishmaniasis in Brazil: revisiting paradigms of epidemiology and control

Visceral leishmaniasis in Brazil: revisiting paradigms of epidemiology and control

Lutzomyia longipalpis and the eco-epidemiology of American visceral leishmaniasis, with particular reference to Brazil: a review

Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis

Contact Info

Product

Resources

About